Ranitidine and Theophylline

Publisher Website
Google Scholar
Abstract
To the editor: The newly available histamine (H2) receptor antagonist, ranitidine hydrochloride (Zantac; Glaxo Inc. , Fort Lauderdale, Florida) has been approved for short-term treatment of duodenal ulcer. Ranitidine is four to eight times more potent than Cimetidine for inhibiting gastric acid secretions (1). As the use of ranitidine increases, reports of its interaction with other drugs such as warfarin and metoprolol are appearing (2). We report a case of theophylline toxicity induced by toxic elevation of serum theophylline levels after initiation of ranitidine therapy. A 75-year-old man with a history of chronic obstructive pulmonary disease with bronchospasm, peptic ulcer

This publication has 0 references indexed in Scilit: